Two sets of phase II trials of a new drug designed to treat people with allergic diseases have been launched.

Cytos Biotechnology said it had launched trials to examine the safety, tolerability and efficacy of Immunodrug CYT003-QbG10 when used to treat people suffering from allergic rhinoconjunctivitis.

The first study will look at the effect of increasing doses of CYT003-QbG10 when used by itself to treat 64 patients with forms of the condition caused by dust mites or cats, compared with the results of a control group taking a placebo.

Trial two will have 100 subjects who have dust mite allergies and compare the performance of a "specific immunotherapy combining allergen extract of house dust mites with CYT003-QbG10" and that of a placebo, the firm announced.

According to the World Allergy Organisation, allergic conjunctivitis is a condition which causes the membrane covering the inner eyelid to be inflamed and in serious cases can damage sight.

Medical professionals caring for patients with a unique unmet need can contact Masters to source drugs undergoing clinical trials.

The firm has many years of experience of providing global healthcare solutions in countries around the world.